Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111,111,111
-
Number of holders
-
238
-
Total 13F shares, excl. options
-
94,465,807
-
Shares change
-
-694,120
-
Total reported value, excl. options
-
$1,681,500,579
-
Value change
-
-$12,863,877
-
Put/Call ratio
-
16.44%
-
Number of buys
-
129
-
Number of sells
-
-99
-
Price
-
$17.8
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q2 2025
283 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q2 2025.
NovoCure Ltd - Common Stock (NVCR) has 238 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94,465,807 shares
of 111,111,111 outstanding shares and own 85.02% of the company stock.
Largest 10 shareholders include FMR LLC (16,722,755 shares), BlackRock, Inc. (14,114,484 shares), VANGUARD GROUP INC (10,752,396 shares), Soleus Capital Management, L.P. (6,904,302 shares), Capital World Investors (6,382,848 shares), STATE STREET CORP (2,678,072 shares), GEODE CAPITAL MANAGEMENT, LLC (2,444,436 shares), Balyasny Asset Management L.P. (2,270,076 shares), MARSHALL WACE, LLP (1,414,599 shares), and UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC (1,371,531 shares).
This table shows the top 238 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.